Clinical Trial Update: TRUDI: TDXD+Durva in HER2+/Low IBC [Phase 2]

View source ↗

Summary

Phase 2 trial TRUDI is evaluating trastuzumab deruxtecan (TDXd) plus durvalumab (Durva) in HER2-positive and HER2-low invasive and inflammatory breast cancer an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Inflammatory Breast Cancer
• Invasive Breast Cancer
• Low Breast Cancer

Drugs mentioned

• Durva (Durvalumab)
• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Filipa Lynce, MD | Conditions: Invasive Breast Cancer, Inflammatory Breast Cancer Stage III | Phase 2 | Status: RECRUITING